{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-11T14:27:22.650403+00:00","company":{"ticker":"NEO","cik":1077183,"company_name":"NEOGENOMICS INC"},"pagination":{"limit":100,"returned":65,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"U.S. Bank Trust Company, National Association","detail":"notes_offering","count":1,"first_seen":"2026-06-22T21:17:36+00:00","last_seen":"2026-06-22T21:17:36+00:00","evidence_fact_ids":[201909]},{"display_name":"certain financial institutions","detail":"other","count":1,"first_seen":"2026-06-22T21:17:36+00:00","last_seen":"2026-06-22T21:17:36+00:00","evidence_fact_ids":[201910]}]},"facts":[{"fact_type":"material_agreement","fact_key":"7c5b5d74a50995d936657ad8980fadb9ddc41ee7","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2026-06-22T21:17:36+00:00","payload":{"action":"entry","agreement_name":"Capped Call Transactions","agreement_type":"other","counterparty":"certain financial institutions (the \"Option Counterparties\")","effective_date":"2026-06-16","item_codes_triggered":["1.01"],"value_text":"approximately $28.7 million"},"claim":"NEOGENOMICS INC entered into Capped Call Transactions with certain financial institutions (the \"Option Counterparties\") valued at approximately $28.7 million (effective 2026-06-16).","evidence_excerpt":"On June 16, 2026, in connection with the pricing of the Initial Notes, the Company entered into privately negotiated capped call transactions (the \"Base Capped Call Transactions\") with certain financial institutions (the \"Option Counterparties\").","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001077183-26-000037","anchor_url":"https://secwatch.observer/filing/0001077183-26-000037#claim-7c5b5d74a50995d936657ad8980fadb9ddc41ee7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718326000037/0001077183-26-000037-index.htm"},{"fact_type":"material_agreement","fact_key":"10bfd6aeafd628934ff58ab6fcca49915483890e","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2026-06-22T21:17:36+00:00","payload":{"action":"entry","agreement_name":"Indenture","agreement_type":"notes_offering","counterparty":"U.S. Bank Trust Company, National Association","effective_date":"2026-06-22","item_codes_triggered":["1.01"],"value_text":"$316.25 million"},"claim":"NEOGENOMICS INC entered into Indenture with U.S. Bank Trust Company, National Association valued at $316.25 million (effective 2026-06-22).","evidence_excerpt":"The Notes were issued pursuant to an Indenture, dated June 22, 2026 (the “Indenture”), by and between the Company and U.S. Bank Trust Company, National Association, as trustee.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001077183-26-000037","anchor_url":"https://secwatch.observer/filing/0001077183-26-000037#claim-10bfd6aeafd628934ff58ab6fcca49915483890e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718326000037/0001077183-26-000037-index.htm"},{"fact_type":"shareholder_vote","fact_key":"daf05dad5d841dd9a5abcf881eed2eb372ca9120","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2026-05-22T20:19:44+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-21","outcome":"passed","proposal_text":"Proposal No. 4: The ratification of the appointment of Deloitte & Touche LLP as the independent registered public accountant.","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"32,158","votes_against":"494,869","votes_for":"116,103,093","votes_withheld":"0"}]},"claim":"NEOGENOMICS INC shareholders approved Proposal No. 4: The ratification of the appointment of Deloitte & Touche LLP as the independent registered public accountant. at the 2026-05-21 meeting.","evidence_excerpt":"Proposal No. 4: The ratification of the appointment of Deloitte & Touche LLP as the independent registered public accountant. The stockholders approved the proposal by the following vote: Number of Votes Outstanding % Voted % For 116,103,093 89.21% 99.57% Against 494,869 0.38% 0.42% Abstentions 32,158 0.02% 0.02%","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001628280-26-037735","anchor_url":"https://secwatch.observer/filing/0001628280-26-037735#claim-daf05dad5d841dd9a5abcf881eed2eb372ca9120","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000162828026037735/0001628280-26-037735-index.htm"},{"fact_type":"shareholder_vote","fact_key":"ac8d8b67bc8828a50b5f64129827e748ec71d564","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2026-05-22T20:19:44+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-21","outcome":"passed","proposal_text":"Proposal No. 3: The approval of the Amendment (Second Amendment of the 2023 Equity Incentive Plan), as identified in the proxy statement for the Annual Meeting.","proposal_type":"equity_plan","results":[{"broker_non_votes":"6,257,933","subject":null,"votes_abstain":"52,772","votes_against":"2,308,922","votes_for":"108,010,493","votes_withheld":"0"}]},"claim":"NEOGENOMICS INC shareholders approved Proposal No. 3: The approval of the Amendment (Second Amendment of the 2023 Equity Incentive Plan), as identified in the proxy statement for the Annual Meeting. at the 2026-05-21 meeting.","evidence_excerpt":"Proposal No. 3: The approval of the Amendment, as identified in the proxy statement for the Annual Meeting. The stockholders approved the proposal by the following vote: Number of Votes Outstanding % Voted % For 108,010,493 82.99% 97.90% Against 2,308,922 1.77% 2.09% Abstentions 52,772 0.04% 0.04% Broker Non-Votes 6,257,933","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001628280-26-037735","anchor_url":"https://secwatch.observer/filing/0001628280-26-037735#claim-ac8d8b67bc8828a50b5f64129827e748ec71d564","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000162828026037735/0001628280-26-037735-index.htm"},{"fact_type":"shareholder_vote","fact_key":"7656731d465e0842777aed37fad0d864aeaa9ff1","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2026-05-22T20:19:44+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-21","outcome":"passed","proposal_text":"Proposal No. 2: The approval, on an advisory basis, of the compensation paid to the Company’s Named Executive Officers, as identified in the proxy statement for the Annual Meeting.","proposal_type":"say_on_pay","results":[{"broker_non_votes":"6,257,933","subject":null,"votes_abstain":"56,118","votes_against":"18,534,236","votes_for":"91,781,833","votes_withheld":"0"}]},"claim":"NEOGENOMICS INC shareholders approved Proposal No. 2: The approval, on an advisory basis, of the compensation paid to the Company’s Named Executive Officers, as identified in the proxy statement for the Annual Meeting. at the 2026-05-21 meeting.","evidence_excerpt":"Proposal No. 2: The approval, on an advisory basis, of the compensation paid to the Company’s Named Executive Officers, as identified in the proxy statement for the Annual Meeting. The advisory approval received an affirmative vote of a majority of the votes cast by stockholders as follows: Number of Votes Outstanding % Voted % For 91,781,833 70.52% 83.19% Against 18,534,236 14.24% 16.80% Abstentions 56,118 0.04% 0.05% Broker Non-Votes 6,257,933","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001628280-26-037735","anchor_url":"https://secwatch.observer/filing/0001628280-26-037735#claim-7656731d465e0842777aed37fad0d864aeaa9ff1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000162828026037735/0001628280-26-037735-index.htm"},{"fact_type":"shareholder_vote","fact_key":"a7998a39ad8d1d51cebb029ede43c87d7fe47d0f","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2026-05-22T20:19:44+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-21","outcome":"passed","proposal_text":"Proposal No. 1: The election of Lynn A. Tetrault, Dr. Marjorie C. Green, Dr. Neil Gunn, Stephen M. Kanovsky, Michael A. Kelly, John P. Kenny, David B. Perez, Felicia Williams and Anthony P. Zook to serve as members of the Board of Directors until the next succeeding annual meeting of stockholders or","proposal_type":"director_election","results":[{"broker_non_votes":"6,257,933","subject":"Lynn A. Tetrault","votes_abstain":"1,276,412","votes_against":"3,367,912","votes_for":"105,727,863","votes_withheld":"0"},{"broker_non_votes":"6,257,933","subject":"Dr. Marjorie C. Green","votes_abstain":"74,464","votes_against":"778,682","votes_for":"109,519,041","votes_withheld":"0"},{"broker_non_votes":"6,257,933","subject":"Dr. Neil Gunn","votes_abstain":"75,455","votes_against":"2,945,140","votes_for":"107,351,592","votes_withheld":"0"},{"broker_non_votes":"6,257,933","subject":"Stephen M. Kanovsky","votes_abstain":"102,681","votes_against":"973,974","votes_for":"109,295,532","votes_withheld":"0"},{"broker_non_votes":"6,257,933","subject":"Michael A. Kelly","votes_abstain":"58,058","votes_against":"5,604,891","votes_for":"104,709,238","votes_withheld":"0"},{"broker_non_votes":"6,257,933","subject":"John P. Kenny","votes_abstain":"75,204","votes_against":"268,748","votes_for":"110,028,235","votes_withheld":"0"},{"broker_non_votes":"6,257,933","subject":"David B. Perez","votes_abstain":"66,518","votes_against":"3,425,136","votes_for":"106,880,533","votes_withheld":"0"},{"broker_non_votes":"6,257,933","subject":"Felicia Williams","votes_abstain":"93,776","votes_against":"792,263","votes_for":"109,486,148","votes_withheld":"0"},{"broker_non_votes":"6,257,933","subject":"Anthony P. Zook","votes_abstain":"57,697","votes_against":"657,836","votes_for":"109,656,654","votes_withheld":"0"}]},"claim":"NEOGENOMICS INC shareholders approved Proposal No. 1: The election of Lynn A. Tetrault, Dr. Marjorie C. Green, Dr. Neil Gunn, Stephen M. Kanovsky, Michael A. Kelly, John P. Kenny, David B. Perez, Felicia Williams and Anthony P. Zook to serve as members of the Board of Directors until the next succeeding annual meeting of stockholders or at the 2026-05-21 meeting.","evidence_excerpt":"Proposal No. 1: The election of Lynn A. Tetrault, Dr. Marjorie C. Green, Dr. Neil Gunn, Stephen M. Kanovsky, Michael A. Kelly, John P. Kenny, David B. Perez, Felicia Williams and Anthony P. Zook to serve as members of the Board of Directors until the next succeeding annual meeting of stockholders or until his or her successor has been duly elected and qualified.  The stockholders elected the nine directors by the following votes: Votes For Votes Against Abstentions Broker Non-Votes Lynn A. Tetrault 105,727,863 3,367,912 1,276,412 6,257,933 Dr. Marjorie C. Green 109,519,041 778,682 74,464 6,257,933 Dr. Neil Gunn 107,351,592 2,945,140 75,455 6,257,933 Stephen M. Kanovsky 109,295,532 973,974 102,681 6,257,933 Michael A. Kelly 104,709,238 5,604,891 58,058 6,257,933 John P. Kenny 110,028,235 268,748 75,204 6,257,933 David B. Perez 106,880,533 3,425,136 66,518 6,257,933 Felicia Williams 109,486,148 792,263 93,776 6,257,933 Anthony P. Zook 109,656,654 657,836 57,697 6,257,933","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001628280-26-037735","anchor_url":"https://secwatch.observer/filing/0001628280-26-037735#claim-a7998a39ad8d1d51cebb029ede43c87d7fe47d0f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000162828026037735/0001628280-26-037735-index.htm"},{"fact_type":"earnings_release","fact_key":"d3f817a1ec98cf5b8c93963156ea60ea4676925a","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2026-04-28T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"full-year 2026","report_date":"2026-04-28","result_type":"guidance_update","revenue_text":"$797-$803 million"},"claim":"NEOGENOMICS INC reported full-year 2026 results: revenue $797-$803 million. Guidance raised.","evidence_excerpt":"Company announces increase in full-year 2026 revenue guidance to a range of $797-$803 million","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-26-000022","anchor_url":"https://secwatch.observer/filing/0001077183-26-000022#claim-d3f817a1ec98cf5b8c93963156ea60ea4676925a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718326000022/0001077183-26-000022-index.htm"},{"fact_type":"earnings_release","fact_key":"9be15aa1cfe2d86b4055403dfbe900a61d75e0c4","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2026-04-28T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":"$17 million","period_text":"first quarter of 2026","report_date":"2026-04-28","result_type":"reported_results","revenue_text":"$187 million"},"claim":"NEOGENOMICS INC reported first quarter of 2026 results: revenue $187 million, net income $17 million. Guidance raised.","evidence_excerpt":"Consolidated revenue for the first quarter of 2026 was $187 million, an increase of 11% over the same period in 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-26-000022","anchor_url":"https://secwatch.observer/filing/0001077183-26-000022#claim-9be15aa1cfe2d86b4055403dfbe900a61d75e0c4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718326000022/0001077183-26-000022-index.htm"},{"fact_type":"executive_change","fact_key":"4b1151c000","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2025-06-24T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-06-19","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Marjorie C. Green was appointed as Director at NEOGENOMICS INC.","evidence_excerpt":"On June 19, 2025, the Board of Directors of NeoGenomics, Inc. (the \"Company\") increased the size of the Board of Directors (the \"Board\") from nine to ten members and appointed Marjorie C. Green as a director to fill the vacancy resulting from that increase.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-25-000145","anchor_url":"https://secwatch.observer/filing/0001077183-25-000145#claim-4b1151c000","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718325000145/0001077183-25-000145-index.htm"},{"fact_type":"governance_change","fact_key":"e40ca99dc59b95ae7674b90f570a1778260fd181","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2025-04-08T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2025-04-04","item_codes_triggered":["5.03"],"summary_text":"Sets forth advance notice procedures and disclosure requirements for stockholder director nominations."},"claim":"NEOGENOMICS INC: Sets forth advance notice procedures and disclosure requirements for stockholder director nominations (effective 2025-04-04).","evidence_excerpt":"On April 4, 2025, the Board of Directors (the \"Board\") of NeoGenomics, Inc. (the \"Company\"), approved an amendment (the \"Amendment\") to the Company's Amended and Restated Bylaws, as amended (the \"Amended and Restated Bylaws\"), effective as of such date.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001077183-25-000067","anchor_url":"https://secwatch.observer/filing/0001077183-25-000067#claim-e40ca99dc59b95ae7674b90f570a1778260fd181","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718325000067/0001077183-25-000067-index.htm"},{"fact_type":"executive_change","fact_key":"68b8fabf65","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2025-03-19T23:59:59+00:00","payload":{"action":"position eliminated","action_category":"departure","departure_tone":"routine","effective_date":"2025-04-01","interim":false,"role":"Chief Operations Officer and President, Oncology Data Solutions","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Melody Harris departed as Chief Operations Officer and President, Oncology Data Solutions at NEOGENOMICS INC.","evidence_excerpt":"Additionally, on March 18, 2025, the Company announced that the Chief Operations Officer and President, Oncology Data Solutions position is being eliminated and as a result, Melody Harris, the current Chief Operations Officer and President, Oncology Data Solutions will no longer hold such role effective April 1, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-25-000052","anchor_url":"https://secwatch.observer/filing/0001077183-25-000052#claim-68b8fabf65","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718325000052/0001077183-25-000052-index.htm"},{"fact_type":"executive_change","fact_key":"2522f9213e","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2025-03-19T23:59:59+00:00","payload":{"action":"promoted","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2025-04-01","interim":false,"role":"President & Chief Operating Officer","role_category":"president","successor_name":null,"successor_named":false},"claim":"Warren Stone changed role as President & Chief Operating Officer at NEOGENOMICS INC.","evidence_excerpt":"On March 18, 2025, NeoGenomics, Inc. (the \"Company\") announced the promotion of Warren Stone, the Company's current Chief Commercial Officer, to the position of President & Chief Operating Officer, effective April 1, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-25-000052","anchor_url":"https://secwatch.observer/filing/0001077183-25-000052#claim-2522f9213e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718325000052/0001077183-25-000052-index.htm"},{"fact_type":"executive_change","fact_key":"8d6d0c72ab","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2025-03-18T23:59:59+00:00","payload":{"action":"departing","action_category":"departure","departure_tone":"routine","effective_date":"2025-04-01","interim":false,"role":"Chief Operations Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Melody Harris departed as Chief Operations Officer at NEOGENOMICS INC.","evidence_excerpt":"Additionally, on March 18, 2024, the Company announced that the Chief Operations Officer position is being eliminated and as a result, Melody Harris, the current Chief Operations Officer, will no longer hold such role and will no longer be a named executive officer effective April 1, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-25-000048","anchor_url":"https://secwatch.observer/filing/0001077183-25-000048#claim-8d6d0c72ab","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718325000048/0001077183-25-000048-index.htm"},{"fact_type":"executive_change","fact_key":"f13d5c070f","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2025-03-18T23:59:59+00:00","payload":{"action":"promoted","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2025-04-01","interim":false,"role":"President & Chief Operating Officer","role_category":"president","successor_name":null,"successor_named":false},"claim":"Warren Stone changed role as President & Chief Operating Officer at NEOGENOMICS INC.","evidence_excerpt":"On March 18, 2025, NeoGenomics, Inc. (the \"Company\") announced the promotion of Warren Stone, the Company's current Chief Commercial Officer, to the position of President & Chief Operating Officer, effective April 1, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-25-000048","anchor_url":"https://secwatch.observer/filing/0001077183-25-000048#claim-f13d5c070f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718325000048/0001077183-25-000048-index.htm"},{"fact_type":"executive_change","fact_key":"49c209d877","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2025-01-10T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-04-01","interim":false,"role":"special advisor","role_category":"other","successor_name":null,"successor_named":false},"claim":"Christopher Smith was appointed as special advisor at NEOGENOMICS INC.","evidence_excerpt":"The Special Advisor Agreement provides that Mr. Smith will serve as a special advisor to the Company’s Chief Executive Officer until February 26, 2027 in exchange for a fee of $23,913 per month.","confidence":0.85,"filing_url":"https://secwatch.observer/filing/0001077183-25-000005","anchor_url":"https://secwatch.observer/filing/0001077183-25-000005#claim-49c209d877","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718325000005/0001077183-25-000005-index.htm"},{"fact_type":"executive_change","fact_key":"ca5e09f480","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2025-01-10T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-04-01","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Tony Zook was appointed as Chief Executive Officer at NEOGENOMICS INC.","evidence_excerpt":"On January 10, 2025, the Company announced the appointment of Tony Zook to replace Mr. Smith as Chief Executive Officer effective April 1, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-25-000005","anchor_url":"https://secwatch.observer/filing/0001077183-25-000005#claim-ca5e09f480","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718325000005/0001077183-25-000005-index.htm"},{"fact_type":"executive_change","fact_key":"7af8ea6dba","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2025-01-10T23:59:59+00:00","payload":{"action":"retire","action_category":"departure","departure_tone":"retirement","effective_date":"2025-04-01","interim":false,"role":"member of the board of directors","role_category":"director","successor_name":null,"successor_named":false},"claim":"Christopher Smith departed as member of the board of directors at NEOGENOMICS INC.","evidence_excerpt":"Christopher Smith, the Company’s Chief Executive Officer and a member of the Company’s board of directors (the “Board”), will retire effective April 1, 2025","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001077183-25-000005","anchor_url":"https://secwatch.observer/filing/0001077183-25-000005#claim-7af8ea6dba","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718325000005/0001077183-25-000005-index.htm"},{"fact_type":"executive_change","fact_key":"766ec424ab","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2025-01-10T23:59:59+00:00","payload":{"action":"retire","action_category":"departure","departure_tone":"retirement","effective_date":"2025-04-01","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":"Tony Zook","successor_named":true},"claim":"Christopher Smith departed as Chief Executive Officer at NEOGENOMICS INC.","evidence_excerpt":"Christopher Smith, the Company’s Chief Executive Officer and a member of the Company’s board of directors (the “Board”), will retire effective April 1, 2025","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-25-000005","anchor_url":"https://secwatch.observer/filing/0001077183-25-000005#claim-766ec424ab","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718325000005/0001077183-25-000005-index.htm"},{"fact_type":"executive_change","fact_key":"c464a4bb19","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2024-11-05T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-11-01","interim":false,"role":"member of the Board","role_category":"director","successor_name":null,"successor_named":false},"claim":"Felicia Williams was appointed as member of the Board at NEOGENOMICS INC.","evidence_excerpt":"On November 1, 2024, the Board of Directors of the Company, appointed Felicia Williams to serve as a member of the Board, the Company’s Audit and Finance Committee (the “Audit Committee”) and the Company’s Nominating and Corporate Governance Committee (the “NCG Committee”).","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001077183-24-000153","anchor_url":"https://secwatch.observer/filing/0001077183-24-000153#claim-c464a4bb19","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718324000153/0001077183-24-000153-index.htm"},{"fact_type":"earnings_release","fact_key":"646b2e0043931b0c9ce7afc6740859425f705a8b","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2024-04-30T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"Net loss of $27 million","period_text":"the period ended March 31, 2024","report_date":"2024-04-30","result_type":"reported_results","revenue_text":"$156 million"},"claim":"NEOGENOMICS INC reported the period ended March 31, 2024 results: revenue $156 million, net income Net loss of $27 million. Guidance reaffirmed.","evidence_excerpt":"NeoGenomics Reports First Quarter 2024 Results First Quarter Revenue Increased 14% to $156 Million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001077183-24-000052","anchor_url":"https://secwatch.observer/filing/0001077183-24-000052#claim-646b2e0043931b0c9ce7afc6740859425f705a8b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718324000052/0001077183-24-000052-index.htm"},{"fact_type":"executive_change","fact_key":"fe2be444ac","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2024-04-18T23:59:59+00:00","payload":{"action":"will now serve as","action_category":"role_change","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Chief Commercial Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Warren Stone changed role as Chief Commercial Officer at NEOGENOMICS INC.","evidence_excerpt":"Warren Stone, presently the Company's President, Clinical Services will now serve as the Company's Chief Commercial Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-24-000048","anchor_url":"https://secwatch.observer/filing/0001077183-24-000048#claim-fe2be444ac","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718324000048/0001077183-24-000048-index.htm"},{"fact_type":"executive_change","fact_key":"f36dac8f38","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2024-04-18T23:59:59+00:00","payload":{"action":"will now serve as","action_category":"role_change","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Chief Operations Officer and President, Informatics","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Melody Harris changed role as Chief Operations Officer and President, Informatics at NEOGENOMICS INC.","evidence_excerpt":"Melody Harris, presently the Company's President, Enterprise Operations will now serve as the Company's Chief Operations Officer and President, Informatics.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-24-000048","anchor_url":"https://secwatch.observer/filing/0001077183-24-000048#claim-f36dac8f38","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718324000048/0001077183-24-000048-index.htm"},{"fact_type":"executive_change","fact_key":"d0f80631ae","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2024-04-18T23:59:59+00:00","payload":{"action":"will no longer hold such role","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"President, Advanced Diagnostics","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Vishal Sikri changed role as President, Advanced Diagnostics at NEOGENOMICS INC.","evidence_excerpt":"as a result, Vishal Sikri, the current President, Advanced Diagnostics, will no longer hold such role","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-24-000048","anchor_url":"https://secwatch.observer/filing/0001077183-24-000048#claim-d0f80631ae","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718324000048/0001077183-24-000048-index.htm"},{"fact_type":"earnings_release","fact_key":"14fa3ff921c063145d653dec26887c93d053d4ad","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2024-02-20T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"initiated","item_codes_triggered":["2.02"],"net_income_text":"$14 million","period_text":"fourth fiscal quarter of 2023 and full year ended December 31, 2023","report_date":"2024-02-20","result_type":"reported_results","revenue_text":"$156 million"},"claim":"NEOGENOMICS INC reported fourth fiscal quarter of 2023 and full year ended December 31, 2023 results: revenue $156 million, net income $14 million. Guidance initiated.","evidence_excerpt":"forth by specific reference in such filing. \n\n--- EX-99.1 (EX-99.1) ---\n\nNeoGenomics Reports Fourth Quarter and Full Year 2023 Results Fourth Quarter Revenue Increased 12% to $156 million; Full Year Revenue Increased 16% to $592 million Fort Myers, Florida, (February 20, 2024) - NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”) , a leading provider of oncology","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-24-000009","anchor_url":"https://secwatch.observer/filing/0001077183-24-000009#claim-14fa3ff921c063145d653dec26887c93d053d4ad","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718324000009/0001077183-24-000009-index.htm"},{"fact_type":"earnings_release","fact_key":"84b163317de7cda565f593ba4f743c67748d6829","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2023-11-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":"$19 million","period_text":"its third fiscal quarter of 2023","report_date":"2023-11-06","result_type":"reported_results","revenue_text":"$152 million"},"claim":"NEOGENOMICS INC reported its third fiscal quarter of 2023 results: revenue $152 million, net income $19 million. Guidance raised.","evidence_excerpt":"as expressly set forth by specific reference in such filing. \n\n--- EX-99.1 (EX-99.1) ---\n\nNeoGenomics Reports Third Quarter 2023 Results Third Quarter Revenue Increased 18% to $152 Million Fort Myers, Florida (November 6, 2023) - NeoGenomics, Inc. (NASDAQ: NEO) (the “ Company ” ), a leading oncology testing services company, today announced its third-quarter","confidence":0.97,"filing_url":"https://secwatch.observer/filing/0001077183-23-000136","anchor_url":"https://secwatch.observer/filing/0001077183-23-000136#claim-84b163317de7cda565f593ba4f743c67748d6829","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718323000136/0001077183-23-000136-index.htm"},{"fact_type":"earnings_release","fact_key":"b407e064d315d9d8907bc89bc9863bdca1358cf4","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2023-08-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":"$24 million","period_text":"second fiscal quarter of 2023","report_date":"2023-08-08","result_type":"reported_results","revenue_text":"$147 million"},"claim":"NEOGENOMICS INC reported second fiscal quarter of 2023 results: revenue $147 million, net income $24 million. Guidance raised.","evidence_excerpt":"as expressly set forth by specific reference in such filing. \n\n--- EX-99.1 (EX-99.1) ---\n\nNeoGenomics Reports Second Quarter 2023 Results Second Quarter Revenue Increased 18% to $147 Million Fort Myers, Florida (August 8, 2023) - NeoGenomics, Inc. (NASDAQ: NEO) (the “ Company ” ), a leading oncology testing services company, today announced its second-quarter results","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-23-000099","anchor_url":"https://secwatch.observer/filing/0001077183-23-000099#claim-b407e064d315d9d8907bc89bc9863bdca1358cf4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718323000099/0001077183-23-000099-index.htm"},{"fact_type":"executive_change","fact_key":"e5c0d11105","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2023-06-29T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-06-26","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Tony Zook was appointed as Director at NEOGENOMICS INC.","evidence_excerpt":"appointed Elizabeth Floegel, Neil Gunn, and Tony Zook as directors to fill the vacancies","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-23-000080","anchor_url":"https://secwatch.observer/filing/0001077183-23-000080#claim-e5c0d11105","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718323000080/0001077183-23-000080-index.htm"},{"fact_type":"executive_change","fact_key":"73e6ea5b35","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2023-06-29T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-06-26","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Neil Gunn was appointed as Director at NEOGENOMICS INC.","evidence_excerpt":"appointed Elizabeth Floegel, Neil Gunn, and Tony Zook as directors to fill the vacancies","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-23-000080","anchor_url":"https://secwatch.observer/filing/0001077183-23-000080#claim-73e6ea5b35","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718323000080/0001077183-23-000080-index.htm"},{"fact_type":"executive_change","fact_key":"c64e9275a7","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2023-06-29T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-06-26","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Elizabeth Floegel was appointed as Director at NEOGENOMICS INC.","evidence_excerpt":"appointed Elizabeth Floegel, Neil Gunn, and Tony Zook as directors to fill the vacancies","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-23-000080","anchor_url":"https://secwatch.observer/filing/0001077183-23-000080#claim-c64e9275a7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718323000080/0001077183-23-000080-index.htm"},{"fact_type":"executive_change","fact_key":"faf7952166","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2023-06-29T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-06-26","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Rachel Stahler resigned as Director at NEOGENOMICS INC.","evidence_excerpt":"On June 26, 2023, Rachel Stahler provided NeoGenomics, Inc., a Nevada corporation (the “Company”), with notice of her resignation from the Board of Directors of the Company (the “Board”), effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-23-000080","anchor_url":"https://secwatch.observer/filing/0001077183-23-000080#claim-faf7952166","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718323000080/0001077183-23-000080-index.htm"},{"fact_type":"shareholder_vote","fact_key":"e826cf36a36804f4d645b142e4a726b5a8ca3304","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2023-05-30T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-25","outcome":"passed","proposal_text":"Ratification of appointment of independent registered public accountant","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"37,969","votes_against":"163,098","votes_for":"113,191,746","votes_withheld":null}]},"claim":"NEOGENOMICS INC shareholders approved Ratification of appointment of independent registered public accountant at the 2023-05-25 meeting.","evidence_excerpt":"Number of Votes Outstanding % Voted % For 113,191,746 88.73% 99.82% Against 163,098 0.12% 0.14% Abstentions 37,969 0.02% 0.04%","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001077183-23-000068","anchor_url":"https://secwatch.observer/filing/0001077183-23-000068#claim-e826cf36a36804f4d645b142e4a726b5a8ca3304","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718323000068/0001077183-23-000068-index.htm"},{"fact_type":"shareholder_vote","fact_key":"3f6d6c3a9d9db5247424dc80d2f7b184f5124330","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2023-05-30T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-25","outcome":"passed","proposal_text":"Approval of NeoGenomics, Inc. 2023 Equity Incentive Plan","proposal_type":"equity_plan","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"52,732","votes_against":"4,930,366","votes_for":"100,799,248","votes_withheld":null}]},"claim":"NEOGENOMICS INC shareholders approved Approval of NeoGenomics, Inc. 2023 Equity Incentive Plan at the 2023-05-25 meeting.","evidence_excerpt":"Number of Votes Outstanding % Voted % For 100,799,248 79.02% 95.28% Against 4,930,366 3.86% 4.67% Abstentions 52,732 0.04% 0.05%","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001077183-23-000068","anchor_url":"https://secwatch.observer/filing/0001077183-23-000068#claim-3f6d6c3a9d9db5247424dc80d2f7b184f5124330","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718323000068/0001077183-23-000068-index.htm"},{"fact_type":"shareholder_vote","fact_key":"65873b760eb9a04052aecf6cc82fdfa2091e192e","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2023-05-30T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-25","outcome":"passed","proposal_text":"Advisory approval of compensation paid to Named Executive Officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"2,998,666","votes_against":"47,993,647","votes_for":"54,790,033","votes_withheld":null}]},"claim":"NEOGENOMICS INC shareholders approved Advisory approval of compensation paid to Named Executive Officers at the 2023-05-25 meeting.","evidence_excerpt":"Number of Votes Outstanding % Voted % For 54,790,033 42.95% 51.79% Against 47,993,647 37.62% 45.37% Abstentions 2,998,666 2.35% 2.84%","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001077183-23-000068","anchor_url":"https://secwatch.observer/filing/0001077183-23-000068#claim-65873b760eb9a04052aecf6cc82fdfa2091e192e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718323000068/0001077183-23-000068-index.htm"},{"fact_type":"shareholder_vote","fact_key":"e3231bacb44ff775cd68615658c1daec648ead56","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2023-05-30T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-05-25","outcome":"passed","proposal_text":"Election of eight directors to serve until the next annual meeting","proposal_type":"director_election","results":[{"broker_non_votes":"7,610,467","subject":"Lynn A. Tetrault","votes_abstain":null,"votes_against":null,"votes_for":"100,261,190","votes_withheld":"5,521,156"},{"broker_non_votes":"7,610,467","subject":"Christopher M. Smith","votes_abstain":null,"votes_against":null,"votes_for":"105,547,399","votes_withheld":"234,947"},{"broker_non_votes":"7,610,467","subject":"Bruce K. Crowther","votes_abstain":null,"votes_against":null,"votes_for":"99,204,967","votes_withheld":"6,577,379"},{"broker_non_votes":"7,610,467","subject":"Dr. Alison L. Hannah","votes_abstain":null,"votes_against":null,"votes_for":"104,720,275","votes_withheld":"1,062,071"},{"broker_non_votes":"7,610,467","subject":"Stephen M. Kanovsky","votes_abstain":null,"votes_against":null,"votes_for":"104,579,362","votes_withheld":"1,202,984"},{"broker_non_votes":"7,610,467","subject":"Michael A. Kelly","votes_abstain":null,"votes_against":null,"votes_for":"97,173,743","votes_withheld":"8,608,603"},{"broker_non_votes":"7,610,467","subject":"David B. Perez","votes_abstain":null,"votes_against":null,"votes_for":"105,656,424","votes_withheld":"125,922"},{"broker_non_votes":"7,610,467","subject":"Rachel A. Stahler","votes_abstain":null,"votes_against":null,"votes_for":"104,833,843","votes_withheld":"948,503"}]},"claim":"NEOGENOMICS INC shareholders approved Election of eight directors to serve until the next annual meeting at the 2023-05-25 meeting.","evidence_excerpt":"Lynn A. Tetrault 100,261,190 5,521,156 — 7,610,467 Christopher M. Smith 105,547,399 234,947 — 7,610,467 Bruce K. Crowther 99,204,967 6,577,379 — 7,610,467 Dr. Alison L. Hannah 104,720,275 1,062,071 — 7,610,467 Stephen M. Kanovsky 104,579,362 1,202,984 — 7,610,467 Michael A. Kelly 97,173,743 8,608,603 — 7,610,467 David B. Perez 105,656,424 125,922 — 7,610,467 Rachel A. Stahler 104,833,843 948,503 — 7,610,467","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001077183-23-000068","anchor_url":"https://secwatch.observer/filing/0001077183-23-000068#claim-e3231bacb44ff775cd68615658c1daec648ead56","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718323000068/0001077183-23-000068-index.htm"},{"fact_type":"earnings_release","fact_key":"bd02b1e30693984cdbd1fd21d9c5dc3ae0e852c5","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2023-05-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$31 million","period_text":"first quarter of 2023","report_date":"2023-05-08","result_type":"reported_results","revenue_text":"$137 million"},"claim":"NEOGENOMICS INC reported first quarter of 2023 results: revenue $137 million, net income $31 million.","evidence_excerpt":"First-Quarter Results Consolidated revenue for the first quarter of 2023 was $137 million, an increase of 17% over the same period in 2022. Clinical Services revenue of $115 million was an increase year-over-year of 16%. Clinical test volume (1) increased by 7% year-over-year. Average revenue per clinical test (“revenue per test”) increased by 8% to $402. Pharma Services revenue increased by 22% to $22 million compared to the first quarter of 2022. Consolidated gross profit for the first quarter of 2023 was $54.8 million, an increase of 43.4% compared to the first quarter of 2022. This increase was primarily due to an increase in revenue partially offset by higher payroll and payroll-related costs and an increase in supplies expense. Consolidated gross profit margin, including amortization of acquired Inivata developed technology intangible assets, was 39.9%. Adjusted Gross Profit Margin (2) , excluding amortization of acquired Inivata developed technology intangible assets, was 43.5%.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001077183-23-000039","anchor_url":"https://secwatch.observer/filing/0001077183-23-000039#claim-bd02b1e30693984cdbd1fd21d9c5dc3ae0e852c5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718323000039/0001077183-23-000039-index.htm"},{"fact_type":"earnings_release","fact_key":"0e66ba2d01f7539614c4e2510beb60e86be77638","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2023-02-23T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"initiated","item_codes_triggered":["2.02"],"net_income_text":"$144 million","period_text":"full year ended December 31, 2022","report_date":"2023-02-23","result_type":"reported_results","revenue_text":"$510 million"},"claim":"NEOGENOMICS INC reported full year ended December 31, 2022 results: revenue $510 million, net income $144 million. Guidance initiated.","evidence_excerpt":"Consolidated revenue for 2022 was $510 million, an increase of 5% over 2021.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001077183-23-000019","anchor_url":"https://secwatch.observer/filing/0001077183-23-000019#claim-0e66ba2d01f7539614c4e2510beb60e86be77638","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718323000019/0001077183-23-000019-index.htm"},{"fact_type":"earnings_release","fact_key":"fbba58cefe4fab335f7d2c516a570552308fccf8","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2023-02-23T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"initiated","item_codes_triggered":["2.02"],"net_income_text":"$23 million","period_text":"the fourth quarter of 2022","report_date":"2023-02-23","result_type":"reported_results","revenue_text":"$139 million"},"claim":"NEOGENOMICS INC reported the fourth quarter of 2022 results: revenue $139 million, net income $23 million. Guidance initiated.","evidence_excerpt":"Consolidated revenue for the fourth quarter of 2022 was $139 million, an increase of 10% over the same period in 2021.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001077183-23-000019","anchor_url":"https://secwatch.observer/filing/0001077183-23-000019#claim-fbba58cefe4fab335f7d2c516a570552308fccf8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718323000019/0001077183-23-000019-index.htm"},{"fact_type":"executive_change","fact_key":"4a1c23a319","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2023-01-23T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-01-19","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"David J. Daly resigned as Director at NEOGENOMICS INC.","evidence_excerpt":"On January 19, 2023, David J. Daly provided NeoGenomics, Inc., a Nevada corporation (the “Company”), with notice of his resignation from the Board of Directors of the Company (the “Board”), effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-23-000008","anchor_url":"https://secwatch.observer/filing/0001077183-23-000008#claim-4a1c23a319","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718323000008/0001077183-23-000008-index.htm"},{"fact_type":"executive_change","fact_key":"6f41803919","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2022-12-06T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-12-07","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Jeffrey S. Sherman was appointed as Chief Financial Officer at NEOGENOMICS INC.","evidence_excerpt":"On December 5, 2022, the Company appointed Jeffrey S. Sherman, age 57, as Chief Financial Officer of the Company, effective December 7, 2022","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001077183-22-000197","anchor_url":"https://secwatch.observer/filing/0001077183-22-000197#claim-6f41803919","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000197/0001077183-22-000197-index.htm"},{"fact_type":"executive_change","fact_key":"0d30c47073","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2022-11-18T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-12-05","interim":false,"role":"President, Enterprise Operations","role_category":"president","successor_name":null,"successor_named":false},"claim":"Melody Harris was appointed as President, Enterprise Operations at NEOGENOMICS INC.","evidence_excerpt":"On November 14, 2022, the Company appointed Melody Harris, age 56, President, Enterprise Operations of the Company, effective December 5, 2022 (the “Effective Date”).","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001077183-22-000176","anchor_url":"https://secwatch.observer/filing/0001077183-22-000176#claim-0d30c47073","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000176/0001077183-22-000176-index.htm"},{"fact_type":"earnings_release","fact_key":"981fd74031d2bf6aade45d7260b9ad24fc09e930","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2022-11-08T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$37 million","period_text":"the third quarter of 2022","report_date":"2022-11-08","result_type":"reported_results","revenue_text":"$129 million"},"claim":"NEOGENOMICS INC reported the third quarter of 2022 results: revenue $129 million, net income $37 million.","evidence_excerpt":"Third-Quarter Results Consolidated revenue for the third quarter of 2022 was $129 million, an increase of 6% over the same period in 2021. Clinical Services revenue of $106 million was an increase year-over-year of 4%. Clinical test volume (1) decreased by 1% year-over-year. Average revenue per clinical test (“revenue per test”) increased by 5% to $392. Pharma Services revenue increased by 18% to $23 million compared to the third quarter of 2021. Consolidated gross profit for the third quarter of 2022 was $48.9 million, an increase of 4% compared to the third quarter of 2021. This increase was primarily due to an increase in revenue partially offset by higher payroll and payroll-related costs. Consolidated gross profit margin, including amortization of acquired Inivata developed technology intangible assets, was 38.0%. Adjusted Gross Profit Margin (2) , excluding amortization of acquired Inivata developed technology intangible assets, was 41.7%. Operating expenses for the third quarter","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001077183-22-000169","anchor_url":"https://secwatch.observer/filing/0001077183-22-000169#claim-981fd74031d2bf6aade45d7260b9ad24fc09e930","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000169/0001077183-22-000169-index.htm"},{"fact_type":"executive_change","fact_key":"9b3ee880f5","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2022-11-07T23:59:59+00:00","payload":{"action":"departed","action_category":"departure","departure_tone":"not_disclosed","effective_date":"2022-11-04","interim":false,"role":"President, Clinical Services Division","role_category":"other_named_officer","successor_name":"Warren Stone","successor_named":true},"claim":"Dr. David Sholehvar departed as President, Clinical Services Division at NEOGENOMICS INC.","evidence_excerpt":"The Company's former President, Clinical Services Division, Dr. David Sholehvar’s last day at the Company was November 4, 2022","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-22-000163","anchor_url":"https://secwatch.observer/filing/0001077183-22-000163#claim-9b3ee880f5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000163/0001077183-22-000163-index.htm"},{"fact_type":"executive_change","fact_key":"d6db27ba1e","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2022-11-07T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-11-21","interim":false,"role":"President, Clinical Services Division","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Warren Stone was appointed as President, Clinical Services Division at NEOGENOMICS INC.","evidence_excerpt":"On November 2, 2022, the Company appointed Warren Stone, age 50, President, Clinical Services Division of the Company, effective November 21, 2022","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-22-000163","anchor_url":"https://secwatch.observer/filing/0001077183-22-000163#claim-d6db27ba1e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000163/0001077183-22-000163-index.htm"},{"fact_type":"executive_change","fact_key":"91d0e316d5","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2022-11-07T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-11-03","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"David B. Perez was appointed as Director at NEOGENOMICS INC.","evidence_excerpt":"Effective November 3, 2022, the Board of Directors (the “Board”) of NeoGenomics, Inc., a Nevada corporation (the “Company”), appointed David B. Perez to serve as a member of the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-22-000163","anchor_url":"https://secwatch.observer/filing/0001077183-22-000163#claim-91d0e316d5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000163/0001077183-22-000163-index.htm"},{"fact_type":"executive_change","fact_key":"ad67a8207e","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2022-07-21T23:59:59+00:00","payload":{"action":"step down as Interim CEO and resume Chair","action_category":"role_change","departure_tone":"routine","effective_date":"2022-08-15","interim":false,"role":"Chair of the Board","role_category":"chair","successor_name":"Chris Smith","successor_named":true},"claim":"Lynn Tetrault changed role as Chair of the Board at NEOGENOMICS INC.","evidence_excerpt":"In connection with Mr. Smith’s appointment, Lynn Tetrault, Esq. will step down as Interim Chief Executive Officer of the Company and will resume the position of independent Chair of the Board effective August 15, 2022.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001077183-22-000124","anchor_url":"https://secwatch.observer/filing/0001077183-22-000124#claim-ad67a8207e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000124/0001077183-22-000124-index.htm"},{"fact_type":"executive_change","fact_key":"6e03c3eac9","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2022-07-21T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-08-15","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Chris Smith was appointed as Chief Executive Officer at NEOGENOMICS INC.","evidence_excerpt":"On July 21, 2022, NeoGenomics, Inc. (the “Company”) announced that Chris Smith, age 59, was appointed Chief Executive Officer and a member of the board of directors of the Company, effective August 15, 2022 (the “Effective Date”).","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001077183-22-000124","anchor_url":"https://secwatch.observer/filing/0001077183-22-000124#claim-6e03c3eac9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000124/0001077183-22-000124-index.htm"},{"fact_type":"executive_change","fact_key":"bdb3cd7af9","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2022-05-11T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-05-23","interim":false,"role":"President and Chief Commercial Officer, Inivata Division","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Vishal Sikri was appointed as President and Chief Commercial Officer, Inivata Division at NEOGENOMICS INC.","evidence_excerpt":"On May 9, 2022, the Company announced that Vishal Sikri, age 46, was appointed President and Chief Commercial Officer, Inivata Division, of the Company, effective May 23, 2022 (the “Effective Date”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-22-000083","anchor_url":"https://secwatch.observer/filing/0001077183-22-000083#claim-bdb3cd7af9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000083/0001077183-22-000083-index.htm"},{"fact_type":"executive_change","fact_key":"976bd51b80","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2022-05-11T23:59:59+00:00","payload":{"action":"retire","action_category":"departure","departure_tone":"retirement","effective_date":"2022-06-30","interim":false,"role":"President of Inivata","role_category":"other_named_officer","successor_name":"Vishal Sikri","successor_named":true},"claim":"Clive D. Morris departed as President of Inivata at NEOGENOMICS INC.","evidence_excerpt":"On May 5, 2022, Dr. Clive D. Morris, NeoGenomics, Inc.’s (the “Company”) current President of Inivata, informed the Company of his intention to retire from his role effective June 30, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-22-000083","anchor_url":"https://secwatch.observer/filing/0001077183-22-000083#claim-976bd51b80","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000083/0001077183-22-000083-index.htm"},{"fact_type":"executive_change","fact_key":"e5aea639a8","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2022-05-06T23:59:59+00:00","payload":{"action":"assume interim responsibility","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-05-27","interim":true,"role":"Interim President, Pharma Services Division","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Jennifer Rose was appointed as Interim President, Pharma Services Division at NEOGENOMICS INC.","evidence_excerpt":"In connection with Dr. Wallar’s departure, Ms. Jennifer Rose will assume interim responsibility for the Pharma Services Division beginning on May 27, 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001077183-22-000076","anchor_url":"https://secwatch.observer/filing/0001077183-22-000076#claim-e5aea639a8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000076/0001077183-22-000076-index.htm"},{"fact_type":"executive_change","fact_key":"89afad520a","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2022-05-06T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-05-27","interim":false,"role":"President, Pharma Services Division","role_category":"president","successor_name":"Jennifer Rose","successor_named":true},"claim":"Gina M. Wallar resigned as President, Pharma Services Division at NEOGENOMICS INC.","evidence_excerpt":"On May 2, 2022, Dr. Gina M. Wallar, NeoGenomics, Inc.’s (the “Company”) current President, Pharma Services Division, informed the Company of her intention to resign from her role effective May 27, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-22-000076","anchor_url":"https://secwatch.observer/filing/0001077183-22-000076#claim-89afad520a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000076/0001077183-22-000076-index.htm"},{"fact_type":"executive_change","fact_key":"c535fd148f","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2022-03-28T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2022-03-28","interim":false,"role":"Executive Chair","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Lynn A. Tetrault was appointed as Executive Chair at NEOGENOMICS INC.","evidence_excerpt":"the Board appointed Lynn A. Tetrault, Esq. the Company’s non-executive Chair of the Board and Chair of the Culture and Compensation Committee, to serve as Executive Chair and the Company’s principal executive officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-22-086679","anchor_url":"https://secwatch.observer/filing/0001193125-22-086679#claim-c535fd148f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000119312522086679/0001193125-22-086679-index.htm"},{"fact_type":"executive_change","fact_key":"6b1dd52ec7","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2022-03-28T23:59:59+00:00","payload":{"action":"stepped down","action_category":"departure","departure_tone":"routine","effective_date":"2022-03-28","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Mark W. Mallon departed as Chief Executive Officer at NEOGENOMICS INC.","evidence_excerpt":"On March 27, 2022, Mark W. Mallon, Chief Executive Officer (“CEO”) and a member of the Board of Directors (the “Board”) of NeoGenomics, Inc. (the “Company”), stepped down from his positions as CEO and director, effective as of March 28, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-22-086679","anchor_url":"https://secwatch.observer/filing/0001193125-22-086679#claim-6b1dd52ec7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000119312522086679/0001193125-22-086679-index.htm"},{"fact_type":"executive_change","fact_key":"2e00565a91","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2022-03-09T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-03-14","interim":false,"role":"President, Clinical Services Division","role_category":"president","successor_name":null,"successor_named":false},"claim":"David Sholehvar was appointed as President, Clinical Services Division at NEOGENOMICS INC.","evidence_excerpt":"Dr. David Sholehvar, age 54, was appointed President, Clinical Services Division of the Company, effective March 14, 2022","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-22-000047","anchor_url":"https://secwatch.observer/filing/0001077183-22-000047#claim-2e00565a91","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000047/0001077183-22-000047-index.htm"},{"fact_type":"executive_change","fact_key":"d6da562eec","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2022-03-09T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":null,"interim":true,"role":"interim President of Lab Operations","role_category":"president","successor_name":null,"successor_named":false},"claim":"Steven Brodie was appointed as interim President of Lab Operations at NEOGENOMICS INC.","evidence_excerpt":"Dr. Steven Brodie, the Company’s current Senior Vice President, Laboratory Operations, has been appointed the Company’s interim President of Lab Operations.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-22-000047","anchor_url":"https://secwatch.observer/filing/0001077183-22-000047#claim-d6da562eec","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000047/0001077183-22-000047-index.htm"},{"fact_type":"executive_change","fact_key":"58279b94e9","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2022-03-09T23:59:59+00:00","payload":{"action":"retire","action_category":"departure","departure_tone":"retirement","effective_date":"2022-03-31","interim":false,"role":"President and Chief Operating Officer, Laboratory Operations","role_category":"coo","successor_name":"Steven Brodie","successor_named":true},"claim":"George A. Cardoza departed as President and Chief Operating Officer, Laboratory Operations at NEOGENOMICS INC.","evidence_excerpt":"George A. Cardoza, NeoGenomics, Inc.’s (the “Company”) current President and Chief Operating Officer, Laboratory Operations, informed the Company of his intention to retire from his role effective March 31, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-22-000047","anchor_url":"https://secwatch.observer/filing/0001077183-22-000047#claim-58279b94e9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000047/0001077183-22-000047-index.htm"},{"fact_type":"executive_change","fact_key":"0a85000e1d","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2022-01-19T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-01-17","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Kevin Johnson resigned as Director at NEOGENOMICS INC.","evidence_excerpt":"On January 17, 2022, Kevin Johnson provided NeoGenomics, Inc., a Nevada corporation (the “Company”), with notice of his resignation from the Board of Directors of the Company (the “Board”), effective as of January 17, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-22-000005","anchor_url":"https://secwatch.observer/filing/0001077183-22-000005#claim-0a85000e1d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000005/0001077183-22-000005-index.htm"},{"fact_type":"executive_change","fact_key":"675792b621","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2021-11-10T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2022-01-01","interim":false,"role":"Chief Sustainability and Risk Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Kathryn McKenzie was appointed as Chief Sustainability and Risk Officer at NEOGENOMICS INC.","evidence_excerpt":"Kathryn McKenzie, the Company’s current Chief Financial Officer, was appointed Chief Sustainability and Risk Officer of the Company, also effective January 1, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-21-000243","anchor_url":"https://secwatch.observer/filing/0001077183-21-000243#claim-675792b621","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718321000243/0001077183-21-000243-index.htm"},{"fact_type":"executive_change","fact_key":"e709f3a581","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2021-11-10T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-01-01","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"William Bonello was appointed as Chief Financial Officer at NEOGENOMICS INC.","evidence_excerpt":"William Bonello, the Company’s current President, Informatics, was appointed Chief Financial Officer of the Company, effective January 1, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-21-000243","anchor_url":"https://secwatch.observer/filing/0001077183-21-000243#claim-e709f3a581","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718321000243/0001077183-21-000243-index.htm"},{"fact_type":"executive_change","fact_key":"ed37618208","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2021-11-10T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"not_disclosed","effective_date":"2021-11-10","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Douglas VanOort resigned as Director at NEOGENOMICS INC.","evidence_excerpt":"Effective today, Douglas VanOort has resigned from the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-21-000243","anchor_url":"https://secwatch.observer/filing/0001077183-21-000243#claim-ed37618208","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718321000243/0001077183-21-000243-index.htm"},{"fact_type":"executive_change","fact_key":"fb2b08f541","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2021-11-10T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2021-11-10","interim":false,"role":"Member of the Board","role_category":"director","successor_name":null,"successor_named":false},"claim":"David Daly was appointed as Member of the Board at NEOGENOMICS INC.","evidence_excerpt":"On November 4, 2021, the Board of Directors (the “Board”) of NeoGenomics, Inc., a Nevada corporation (the “Company”), voted to appoint David Daly to serve as a member of the Board, effective November 10, 2021.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-21-000243","anchor_url":"https://secwatch.observer/filing/0001077183-21-000243#claim-fb2b08f541","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718321000243/0001077183-21-000243-index.htm"},{"fact_type":"executive_change","fact_key":"f91178d964","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2021-10-12T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2021-10-07","interim":false,"role":"non-executive Chair of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Lynn A. Tetrault was appointed as non-executive Chair of the Board at NEOGENOMICS INC.","evidence_excerpt":"appointed Lynn A. Tetrault, the Company’s Lead Independent Director, as the non-executive Chair of the Board, effective October 7, 2021.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-21-000225","anchor_url":"https://secwatch.observer/filing/0001077183-21-000225#claim-f91178d964","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718321000225/0001077183-21-000225-index.htm"},{"fact_type":"executive_change","fact_key":"e144515666","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2021-10-12T23:59:59+00:00","payload":{"action":"resigned","action_category":"role_change","departure_tone":"retirement","effective_date":"2021-10-07","interim":false,"role":"Executive Chairman and Chairman of the Board","role_category":"chair","successor_name":"Lynn A. Tetrault","successor_named":true},"claim":"Douglas M. VanOort resigned as Executive Chairman and Chairman of the Board at NEOGENOMICS INC.","evidence_excerpt":"Douglas M. VanOort, the former Chief Executive Officer of NeoGenomics, Inc. (the “Company”) and currently the Company’s Executive Chairman and Chairman of the Board of Directors (the “Board”) of the Company, notified the Board of his voluntary decision to retire from the Company and that in connection with his retirement he was tendering his resignation as Executive Chairman and Chairman of the Board of the Company, effective October 7, 2021.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-21-000225","anchor_url":"https://secwatch.observer/filing/0001077183-21-000225#claim-e144515666","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718321000225/0001077183-21-000225-index.htm"},{"fact_type":"executive_change","fact_key":"61bb611d55","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2021-07-15T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2021-06-18","interim":false,"role":"President of Inivata","role_category":"president","successor_name":null,"successor_named":false},"claim":"Clive Morris was appointed as President of Inivata at NEOGENOMICS INC.","evidence_excerpt":"in connection with Mr. Morris’s appointment as President of Inivata.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-21-000190","anchor_url":"https://secwatch.observer/filing/0001077183-21-000190#claim-61bb611d55","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718321000190/0001077183-21-000190-index.htm"},{"fact_type":"executive_change","fact_key":"83bb9fdfa6","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2021-07-07T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2021-07-05","interim":false,"role":"President, Pharma Services Division","role_category":"president","successor_name":null,"successor_named":false},"claim":"Gina M. Wallar was appointed as President, Pharma Services Division at NEOGENOMICS INC.","evidence_excerpt":"The Company announces that Dr. Gina M. Wallar, age 46, has been appointed President, Pharma Services Division effective July 5, 2021 to replace the vacancy left by Mr. Cardoza's assumption of his new position.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-21-000179","anchor_url":"https://secwatch.observer/filing/0001077183-21-000179#claim-83bb9fdfa6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718321000179/0001077183-21-000179-index.htm"},{"fact_type":"executive_change","fact_key":"dd02e728aa","cik":1077183,"ticker":"NEO","company_name":"NEOGENOMICS INC","filed_at":"2021-07-07T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2021-07-05","interim":false,"role":"President and Chief Operating Officer, Lab Operations","role_category":"coo","successor_name":null,"successor_named":false},"claim":"George A. Cardoza was appointed as President and Chief Operating Officer, Lab Operations at NEOGENOMICS INC.","evidence_excerpt":"NeoGenomics, Inc. (the “Company”) announces that George A. Cardoza, age 59, has been appointed President and Chief Operating Officer, Lab Operations effective July 5, 2021.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001077183-21-000179","anchor_url":"https://secwatch.observer/filing/0001077183-21-000179#claim-dd02e728aa","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718321000179/0001077183-21-000179-index.htm"}]}